From: Adenosine receptor expression in rheumatoid synovium: a basis for methotrexate action
Variable | Genotypea | Allelic Pvalue | ||
---|---|---|---|---|
 | 11 | 12 | 22 |  |
SJC (28) | 2.9 ± 3.4 | 2.7 ± 3.9 | 3.0 ± 3.0 | 0.89 |
 | 123 (54.7%) | 84 (37.6%) | 18 (8.2%) |  |
TJC (28) | 2.5 ± 3.5 | 2.4 ± 3.9 | 1.7 ± 2.3 | 0.65 |
 | 123 (54.7%) | 84 (37.6%) | 18 (8.2%) |  |
DAS28 | 2.9 ± 1.2 | 2.9 ± 1.3 | 2.9 ± 1.1 | 0.99 |
 | 123 (54.7%) | 84 (37.6%) | 18 (8.2%) |  |
CRP | 1.2 ± 2.1 | 1.1 ± 1.4 | 1.1 ± 0.9 | 0.98 |
 | 105 (46.7%) | 66 (29.3%) | 16 (7.1%) |  |
Physicians global | 23.5 ± 19.5 | 22.0 ± 19.8 | 15.5 ± 12.7 | 0.26 |
 | 123 (54.7%) | 84 (37.6%) | 18 (8.2%) |  |
Physicians response to MTX | 22.9 ± 18.9 | 22.2 ± 20.7 | 14.5 ± 13.6 | 0.23 |
 | 118 (52.4%) | 71 (9.3%) | 18 (8.2%) |  |
Pain VAS | 23.6 ± 22.8 | 22.8 ± 23.9 | 20.1 ± 22.9 | 0.83 |
 | 123 (54.7%) | 84 (37.6%) | 18 (8.2%) |  |
Patient global | 26.4 ± 21.9 | 27.6 ± 24.6 | 23.7 ± 17.1 | 0.79 |
 | 123 (54.7%) | 84 (37.6%) | 18 (8.2%) |  |
mHAQ | 0.42 ± 0.49 | 0.42 ± 0.45 | 0.37 ± 0.47 | 0.89 |
 | 123 (54.7%) | 84 (37.6%) | 18 (8.2%) |  |